Published in Gastroenterology on May 01, 2003
Turning 'sweet' on immunity: galectin-glycan interactions in immune tolerance and inflammation. Nat Rev Immunol (2009) 3.22
The AP1-dependent secretion of galectin-1 by Reed Sternberg cells fosters immune privilege in classical Hodgkin lymphoma. Proc Natl Acad Sci U S A (2007) 2.31
Concern A beta-oxidation-resistant lipoxin A4 analog treats hapten-induced colitis by attenuating inflammation and immune dysfunction. Proc Natl Acad Sci U S A (2004) 2.13
Regulation of transforming growth factor-β1-driven lung fibrosis by galectin-3. Am J Respir Crit Care Med (2011) 2.09
Insights from advances in research of chemically induced experimental models of human inflammatory bowel disease. World J Gastroenterol (2007) 1.56
Inflammatory bowel disease, past, present and future: lessons from animal models. J Gastroenterol (2008) 1.48
Galectin-1 as a potential cancer target. Br J Cancer (2005) 1.45
Tumor-associated galectin-3 modulates the function of tumor-reactive T cells. Cancer Res (2008) 1.26
Epigenetic maturation in colonic mucosa continues beyond infancy in mice. Hum Mol Genet (2010) 1.06
Suppression of autoimmune diabetes by soluble galectin-1. J Immunol (2009) 1.06
Galectin-1 functions as a Th2 cytokine that selectively induces Th1 apoptosis and promotes Th2 function. Eur J Immunol (2008) 1.05
Galectin-1 reduces the severity of herpes simplex virus-induced ocular immunopathological lesions. J Immunol (2012) 1.00
GITR modulates innate and adaptive mucosal immunity during the development of experimental colitis in mice. Gut (2006) 0.99
Galectin-1 research in T cell immunity: past, present and future. Clin Immunol (2011) 0.98
Galectin-4 controls intestinal inflammation by selective regulation of peripheral and mucosal T cell apoptosis and cell cycle. PLoS One (2008) 0.97
Shedding light on the immunomodulatory properties of galectins: novel regulators of innate and adaptive immune responses. Glycoconj J (2004) 0.87
The coming of age of galectins as immunomodulatory agents: impact of these carbohydrate binding proteins in T cell physiology and chronic inflammatory disorders. Ann Rheum Dis (2005) 0.87
Regulation of galectin-3 function in mucosal fibroblasts: potential role in mucosal inflammation. Clin Exp Immunol (2008) 0.86
Tanshinone IIA ameliorates trinitrobenzene sulfonic acid (TNBS)-induced murine colitis. Dig Dis Sci (2007) 0.86
Galectin-1-mediated suppression of Pseudomonas aeruginosa-induced corneal immunopathology. J Immunol (2013) 0.85
Thymoquinone prevents and ameliorates dextran sulfate sodium-induced colitis in mice. Dig Dis Sci (2012) 0.84
Roles of galectins in inflammatory bowel disease. World J Gastroenterol (2008) 0.84
Modulation of inflammatory response via alpha2-adrenoceptor blockade in acute murine colitis. Clin Exp Immunol (2009) 0.84
The leukocyte activation receptor CD69 controls T cell differentiation through its interaction with galectin-1. Mol Cell Biol (2014) 0.83
Expression of galectins-1, -3 and -4 varies with strain and type of experimental colitis in mice. Int J Exp Pathol (2008) 0.82
The glycan-binding protein galectin-1 controls survival of epithelial cells along the crypt-villus axis of small intestine. Cell Death Dis (2011) 0.80
Galectin-1 induced activation of the mitochondrial apoptotic pathway: evidence for a connection between death-receptor and mitochondrial pathways in human Jurkat T lymphocytes. Histochem Cell Biol (2009) 0.80
Blockade of STAT3 by antisense oligonucleotide in TNBS-induced murine colitis. Int J Colorectal Dis (2006) 0.80
Deregulation of annexin-A1 and galectin-1 expression in precancerous gastric lesions: intestinal metaplasia and gastric ulcer. Mediators Inflamm (2014) 0.80
Ganglioside GM1 deficiency in effector T cells from NOD mice induces resistance to regulatory T-cell suppression. Diabetes (2011) 0.79
Galectins in the Pathogenesis of Rheumatoid Arthritis. J Clin Cell Immunol (2013) 0.79
Duodenal intraepithelial lymphocytes of children with cow milk allergy preferentially bind the glycan-binding protein galectin-3. Int J Immunopathol Pharmacol (2009) 0.79
Inducible colitis-associated glycome capable of stimulating the proliferation of memory CD4+ T cells. J Exp Med (2012) 0.78
Galectins regulate the inflammatory response in airway epithelial cells exposed to microbial neuraminidase by modulating the expression of SOCS1 and RIG1. Mol Immunol (2015) 0.78
Andrographolide derivative AL-1 ameliorates TNBS-induced colitis in mice: involvement of NF-кB and PPAR-γ signaling pathways. Sci Rep (2016) 0.78
Gut mucosal DAMPs in IBD: from mechanisms to therapeutic implications. Mucosal Immunol (2016) 0.77
Comparison of galectin expression signatures in rejected and accepted murine corneal allografts. Cornea (2015) 0.77
Pathobiology of neutrophil-epithelial interactions. Immunol Rev (2016) 0.77
Dual roles of endogenous and exogenous galectin-1 in the control of testicular immunopathology. Sci Rep (2015) 0.76
Knockdown of core 1 beta 1, 3-galactosyltransferase prolongs skin allograft survival with induction of galectin-1 secretion and suppression of CD8+ T cells: T synthase knockdown effects on galectin-1 and CD8+ T cells. J Clin Immunol (2012) 0.76
Engineering galectin-glycan interactions for immunotherapy and immunomodulation. Exp Biol Med (Maywood) (2016) 0.75
Immunohistochemical Studies on Galectin Expression in Colectomised Patients with Ulcerative Colitis. Biomed Res Int (2016) 0.75
The role of Galectin-1 and Galectin-3 in the mucosal immune response to Citrobacter rodentium infection. PLoS One (2014) 0.75
Lack of galectin-1 or galectin-3 alters B cell deletion and anergy in an autoantibody transgene model. Glycobiology (2013) 0.75
Protective Effect of Galectin-1 during Histoplasma capsulatum Infection Is Associated with Prostaglandin E2 and Nitric Oxide Modulation. Mediators Inflamm (2016) 0.75
Anti-inflammatory effect of galectin-1 in a murine model of atopic dermatitis. J Mol Med (Berl) (2017) 0.75
Galectins as modulators of tumour progression. Nat Rev Cancer (2005) 5.30
Hydrogen sulfide is an endogenous modulator of leukocyte-mediated inflammation. FASEB J (2006) 3.37
Gastrointestinal safety of NO-aspirin (NCX-4016) in healthy human volunteers: a proof of concept endoscopic study. Gastroenterology (2003) 3.21
Differential glycosylation of TH1, TH2 and TH-17 effector cells selectively regulates susceptibility to cell death. Nat Immunol (2007) 3.07
Biofeedback is superior to laxatives for normal transit constipation due to pelvic floor dyssynergia. Gastroenterology (2006) 2.98
Protein-glycan interactions in the control of innate and adaptive immune responses. Nat Immunol (2008) 2.77
Galectins: structure, function and therapeutic potential. Expert Rev Mol Med (2008) 2.61
Inhibition of hydrogen sulfide generation contributes to gastric injury caused by anti-inflammatory nonsteroidal drugs. Gastroenterology (2005) 2.58
Targeted inhibition of galectin-1 gene expression in tumor cells results in heightened T cell-mediated rejection; A potential mechanism of tumor-immune privilege. Cancer Cell (2004) 2.46
A comparative study of the anti-inflammatory, anticoagulant, antiangiogenic, and antiadhesive activities of nine different fucoidans from brown seaweeds. Glycobiology (2007) 2.45
The AP1-dependent secretion of galectin-1 by Reed Sternberg cells fosters immune privilege in classical Hodgkin lymphoma. Proc Natl Acad Sci U S A (2007) 2.31
Tolerogenic signals delivered by dendritic cells to T cells through a galectin-1-driven immunoregulatory circuit involving interleukin 27 and interleukin 10. Nat Immunol (2009) 2.23
Galectin-1 deactivates classically activated microglia and protects from inflammation-induced neurodegeneration. Immunity (2012) 2.18
Concern A beta-oxidation-resistant lipoxin A4 analog treats hapten-induced colitis by attenuating inflammation and immune dysfunction. Proc Natl Acad Sci U S A (2004) 2.13
Concern NCX-4016 (NO-aspirin) inhibits lipopolysaccharide-induced tissue factor expression in vivo: role of nitric oxide. Circulation (2002) 2.09
A pivotal role for galectin-1 in fetomaternal tolerance. Nat Med (2007) 2.08
The nuclear receptor SHP mediates inhibition of hepatic stellate cells by FXR and protects against liver fibrosis. Gastroenterology (2004) 1.96
FXR activation reverses insulin resistance and lipid abnormalities and protects against liver steatosis in Zucker (fa/fa) obese rats. J Lipid Res (2009) 1.96
6alpha-ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity. J Med Chem (2002) 1.85
Galectins: regulators of acute and chronic inflammation. Ann N Y Acad Sci (2010) 1.83
A unique galectin signature in human prostate cancer progression suggests galectin-1 as a key target for treatment of advanced disease. Cancer Res (2012) 1.74
The bile acid receptor FXR is a modulator of intestinal innate immunity. J Immunol (2009) 1.69
Gastrointestinal safety and anti-inflammatory effects of a hydrogen sulfide-releasing diclofenac derivative in the rat. Gastroenterology (2006) 1.59
Evidence that hydrogen sulfide exerts antinociceptive effects in the gastrointestinal tract by activating KATP channels. J Pharmacol Exp Ther (2005) 1.56
Viral induction and targeted inhibition of galectin-1 in EBV+ posttransplant lymphoproliferative disorders. Blood (2011) 1.53
Co-administration of nitric oxide-aspirin (NCX-4016) and aspirin prevents platelet and monocyte activation and protects against gastric damage induced by aspirin in humans. J Am Coll Cardiol (2004) 1.52
Aspirin, but not NO-releasing aspirin (NCX-4016), interacts with selective COX-2 inhibitors to aggravate gastric damage and inflammation. Am J Physiol Gastrointest Liver Physiol (2004) 1.47
A novel function for galectin-1 at the crossroad of innate and adaptive immunity: galectin-1 regulates monocyte/macrophage physiology through a nonapoptotic ERK-dependent pathway. J Immunol (2007) 1.46
Bile-acid-activated receptors: targeting TGR5 and farnesoid-X-receptor in lipid and glucose disorders. Trends Pharmacol Sci (2009) 1.45
Targeting galectin-1 overcomes breast cancer-associated immunosuppression and prevents metastatic disease. Cancer Res (2012) 1.44
Endothelial nitric oxide synthase: the Cinderella of inflammation? Trends Pharmacol Sci (2003) 1.43
PAR1 antagonism protects against experimental liver fibrosis. Role of proteinase receptors in stellate cell activation. Hepatology (2004) 1.42
Pseudo-pseudo-obstruction. Eur J Gastroenterol Hepatol (2004) 1.40
The third gas: H2S regulates perfusion pressure in both the isolated and perfused normal rat liver and in cirrhosis. Hepatology (2005) 1.38
Galectin-1 suppresses autoimmune retinal disease by promoting concomitant Th2- and T regulatory-mediated anti-inflammatory responses. J Immunol (2006) 1.37
NCX-1015, a nitric-oxide derivative of prednisolone, enhances regulatory T cells in the lamina propria and protects against 2,4,6-trinitrobenzene sulfonic acid-induced colitis in mice. Proc Natl Acad Sci U S A (2002) 1.36
When galectins recognize glycans: from biochemistry to physiology and back again. Biochemistry (2011) 1.34
Potential cardioprotective actions of no-releasing aspirin. Nat Rev Drug Discov (2002) 1.33
Cyclooxygenase-2-derived lipoxin A4 increases gastric resistance to aspirin-induced damage. Gastroenterology (2002) 1.33
Disrupting galectin-1 interactions with N-glycans suppresses hypoxia-driven angiogenesis and tumorigenesis in Kaposi's sarcoma. J Exp Med (2012) 1.31
A farnesoid x receptor-small heterodimer partner regulatory cascade modulates tissue metalloproteinase inhibitor-1 and matrix metalloprotease expression in hepatic stellate cells and promotes resolution of liver fibrosis. J Pharmacol Exp Ther (2005) 1.30
Antiatherosclerotic effect of farnesoid X receptor. Am J Physiol Heart Circ Physiol (2008) 1.26
Role of galectins in inflammatory and immunomodulatory processes. Biochim Biophys Acta (2002) 1.25
Importance of innate immunity and collagen binding integrin alpha1beta1 in TNBS-induced colitis. Immunity (2002) 1.25
Galectin-3 mediates IL-4-induced survival and differentiation of B cells: functional cross-talk and implications during Trypanosoma cruzi infection. J Immunol (2004) 1.24
Bile acid-activated receptors in the treatment of dyslipidemia and related disorders. Prog Lipid Res (2009) 1.23
Dynamic cross-talk between tumor and immune cells in orchestrating the immunosuppressive network at the tumor microenvironment. Cancer Immunol Immunother (2007) 1.21
Disruption of an SP2/KLF6 repression complex by SHP is required for farnesoid X receptor-induced endothelial cell migration. J Biol Chem (2006) 1.21
NF-kappa B regulates expression of the MHC class I-related chain A gene in activated T lymphocytes. J Immunol (2004) 1.20
CD1-restricted recognition of exogenous and self-lipid antigens by duodenal gammadelta+ T lymphocytes. J Immunol (2007) 1.20
The farnesoid X receptor promotes adipocyte differentiation and regulates adipose cell function in vivo. Mol Pharmacol (2006) 1.20
Tolerance signaling molecules and pregnancy: IDO, galectins, and the renaissance of regulatory T cells. Am J Reprod Immunol (2007) 1.20
Solomonsterols A and B from Theonella swinhoei. The first example of C-24 and C-23 sulfated sterols from a marine source endowed with a PXR agonistic activity. J Med Chem (2010) 1.18
Galectin-3 and soluble fibrinogen act in concert to modulate neutrophil activation and survival: involvement of alternative MAPK pathways. Glycobiology (2004) 1.18
Intracellular retention of the NKG2D ligand MHC class I chain-related gene A in human melanomas confers immune privilege and prevents NK cell-mediated cytotoxicity. J Immunol (2008) 1.17
PPARs and other nuclear receptors in inflammation. Curr Opin Pharmacol (2006) 1.17
Galectin-1 sensitizes resting human T lymphocytes to Fas (CD95)-mediated cell death via mitochondrial hyperpolarization, budding, and fission. J Biol Chem (2004) 1.17
Protective effects of 6-ethyl chenodeoxycholic acid, a farnesoid X receptor ligand, in estrogen-induced cholestasis. J Pharmacol Exp Ther (2005) 1.16
Long-term study on the effects of visual biofeedback and muscle training as a therapeutic modality in pelvic floor dyssynergia and slow-transit constipation. Dis Colon Rectum (2004) 1.15
Retracted A role for proteinase-activated receptor-1 in inflammatory bowel diseases. J Clin Invest (2004) 1.15
Pasta naturally enriched with isoflavone aglycons from soy germ reduces serum lipids and improves markers of cardiovascular risk. J Nutr (2007) 1.15
The bile acid sensor FXR regulates insulin transcription and secretion. Biochim Biophys Acta (2010) 1.11
Interaction of a selective cyclooxygenase-2 inhibitor with aspirin and NO-releasing aspirin in the human gastric mucosa. Proc Natl Acad Sci U S A (2003) 1.11
AP1-dependent galectin-1 expression delineates classical hodgkin and anaplastic large cell lymphomas from other lymphoid malignancies with shared molecular features. Clin Cancer Res (2008) 1.11
The bile acid receptor GPBAR-1 (TGR5) modulates integrity of intestinal barrier and immune response to experimental colitis. PLoS One (2011) 1.11
Cross-talk between farnesoid-X-receptor (FXR) and peroxisome proliferator-activated receptor gamma contributes to the antifibrotic activity of FXR ligands in rodent models of liver cirrhosis. J Pharmacol Exp Ther (2005) 1.11
Role of FXR in regulating bile acid homeostasis and relevance for human diseases. Curr Drug Targets Immune Endocr Metabol Disord (2005) 1.11
Efficacy of the CCR5 antagonist maraviroc in reducing early, ritonavir-induced atherogenesis and advanced plaque progression in mice. Circulation (2013) 1.11
Total synthesis and pharmacological characterization of solomonsterol A, a potent marine pregnane-X-receptor agonist endowed with anti-inflammatory activity. J Med Chem (2011) 1.09
Relative contribution of acetylated cyclo-oxygenase (COX)-2 and 5-lipooxygenase (LOX) in regulating gastric mucosal integrity and adaptation to aspirin. FASEB J (2003) 1.09
Probiotics modulate intestinal expression of nuclear receptor and provide counter-regulatory signals to inflammation-driven adipose tissue activation. PLoS One (2011) 1.08
The enteric nervous system in chagasic and idiopathic megacolon. Am J Surg Pathol (2007) 1.07